Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 8/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451983 | 0.93 | MAPT (0.37) | KDM1ALMNAMEN1KMT2AALOX15 | |
| SCHEMBL3453701 | 0.93 | LMNA (0.39) | POLBLMNAMEN1KMT2AUSP2 | |
| SCHEMBL3453876 | 0.88 | TRPA1 (0.35) | GCGRGIPRLMNAMEN1KMT2A | |
| SCHEMBL3453392 | 0.76 | NPC1 (0.41) | KDM1APAX8MAOARORCPOLB | |
| SCHEMBL3451928 | 0.74 | TRPA1 (0.38) | MEN1KMT2A | |
| SCHEMBL3452514 | 0.74 | RAB9A (0.40) | GCGRGIPRLMNAMEN1KMT2A | |
| SCHEMBL5161880 | 0.73 | RAB9A (0.42) | GCGRGIPRPOLBMEN1KMT2A | |
| SCHEMBL3452789 | 0.72 | DHODH (0.40) | LMNAMEN1KMT2A | |
| SCHEMBL3452543 | 0.72 | MRE11 (0.36) | GCGRGIPR | |
| SCHEMBL5163151 | 0.71 | MEP1B (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | KDM1A 2868/4885PAX8 4179/4885MAOA 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.